BRCA1 and neoplasm: PARP and WEE1 inhibitors in combination is not sufficient to eradicate BRCA1/2 wild-type TNBC tumours regardless of whether they have low (AT3, 4T1ch9) or moderate (AT3OVA) levels of pre-exsiting TILs.